Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

In this open-label Phase II study (n=114), the addition of bevacizumab to carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma improved progression-free survival (median 4.8 v 3.0 months; HR 0.46; 95% CI 0.31 to 0.70; P<0.001).

Journal of Clinical Oncology